EUVIMEDEUVIMED entdecken
Editorial

Weighing the Risks of Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy

Cynthia E Dunbar

New England Journal of Medicine · 2024

DOI: 10.1056/nejme2409399 ↗

Kurz gefasst

Editorial in der Zeitschrift New England Journal of Medicine, 2024. Verfasst von Cynthia E Dunbar. Beteiligte Einrichtung: From the Translational Stem Cell Biology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland. Hauptthemen laut MEDLINE: Adrenoleukodystrophy, Genetic Therapy, Genetic Vectors, Lentivirus. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

More than 30 years ago, the first transplantation with autologous hematopoietic stem cells modified with integrated murine retroviral vectors carrying potentially therapeutic genes was performed in patients with serious human disorders. The past decade has been marked by an acceleration in the publication of data from clinical trials and in regulatory approvals for therapies that use viral gene addition to treat hemoglobinopathies, immunodeficiencies, and metabolic neurologic disorders such as cerebral adrenoleukodystrophy. 1 After the induction of numerous hematologic cancers linked to activation or dysregulation of nearby oncogenes by viral promoter–enhancers contained within the retroviral vector among patients enrolled in early clinical . . .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdrenoleukodystrophyGenetic TherapyGenetic VectorsLentivirusHematologic NeoplasmsHumansClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicClonal EvolutionATP Binding Cassette Transporter, Subfamily D, Member 1Myelodysplastic SyndromesFollow-Up Studies

Substanzen

ABCD1 protein, humanATP Binding Cassette Transporter, Subfamily D, Member 1

Autor:innen und Institutionen

  • From the Translational Stem Cell Biology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.

Zitieren

APA

Dunbar, C. E. (2024). Weighing the Risks of Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy. New England Journal of Medicine. https://doi.org/10.1056/nejme2409399

Vancouver

Dunbar CE. Weighing the Risks of Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy. New England Journal of Medicine. 2024. doi:10.1056/nejme2409399

BibTeX
@article{Dunbar2024,
  author = {Dunbar, Cynthia E},
  title = {Weighing the Risks of Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy},
  journal = {New England Journal of Medicine},
  year = {2024},
  doi = {10.1056/nejme2409399}
}
Kostenlos starten →